

## Systemic Anti-Cancer Therapy (SACT) Newsletter

National Cancer Registration and Analysis Service | Issue 009 | December 2020

Protecting and improving the nation's health

#### Welcome to the latest edition of the SACT newsletter.

We release the newsletter at regular intervals in order to keep SACT colleagues up to date with any developments or new communications.

#### SACT reports

We update all reports on **CancerStats2** each month to include the latest SACT data reported by NHS trusts through their monthly data submissions

Over the past few months, we have added two new reports:

**COVID-19 dashboard** - provides a useful tool for NHS trusts to review their activity during the COVID-19 pandemic, evaluate any trends, help rebuild services, and future proof any current approaches. A new version of the dashboard was released Friday 4 December.

NHS Benchmarking: Pharmacy and medicines optimisation 2019/20 - provides data required by the trusts participating in the NHS Benchmarking Pharmacy Project 2019/20.

Head to the CancerStats2 platform to access all available reports.

#### Public reports on CancerData

We have been developing two COVID-19 dashboards in collaboration with Cancer Research UK which will be publicly available on <a href="CancerData">CancerData</a>. The first dashboard was <a href="published">published</a> on Thursday 3
December and provides an overview of the radiotherapy activity during the pandemic. We aim to release the second dashboard reviewing activity for patients receiving SACT treatments later this year.

## 30-day mortality post-SACT update

#### **Evaluation questionnaire**

On 24 November, we emailed the mortality contacts at each NHS trust to provide the link for our evaluation questionnaire. The aim of this questionnaire is to gather feedback on the recent 30-day mortality data releases and help us to assess the impact and value of the CMAR workbook and Rapid Data Review. The survey is anonymous and also provides the opportunity to suggest changes that suit your needs.

If you have used either of these data releases, we would really appreciate your feedback by completing the <u>questionnaire</u>. We have provided an update on both data feeds in the section below.

#### **Background information**

Since April 2020, we have been providing you with two new 30-day mortality post-SACT data releases:

- Case-mix adjusted rates (CMAR) workbook shared with NHS trusts every 3-5 months and then published on our website 2 months after initial release. The workbook contains case-mix adjusted 30-day mortality post-SACT rates for each trust for a range of cancer sites. Outliers are identified and rates can be used as a performance indicator between trusts. The next workbook will be shared with NHS trusts in February and will include patients treated for Prostate cancer, Acute Myeloid Leukaemia (AML) and Acute Lymphoblastic Leukaemia (ALL). We also plan to release a CTYA workbook early next year which will review patients treated for ALL.
- Rapid Data Review (RDR) shared with NHS trusts quarterly, includes patient data for all patients who appear to have died within 30 days of receiving SACT, across all cancer sites. Trusts only receive data for their own patients; this

## Helpdesk update

We would like to inform you that there will be **limited cover** on the SACT and NDRS datasets helpdesk over the Christmas period. Users should aim to upload data files and complete mappings within the **first three weeks** of December to ensure support is available to assist with any queries.

Thank you for your continued support with SACT and other NDRS datasets.

# SACT API portal—new regimen mapping functionality

We have recently made some improvements to assist trust pharmacists when mapping regimens:

- 1. When searching for a regimen to map, the default list will now be in alphabetical order.
- 2. When searching for a regimen entry on the available list, you can now search for a part name and a full name.

For more information and full examples, please contact the SACT <u>helpdesk</u>.

## **NDRS** webinar series

This autumn, the National Disease Registration Service (NDRS) has hosted a series of free webinars to share information about our latest work and developments; each session focuses on a different area of the service. Visit the NDRS website to view webinar recordings and register for upcoming sessions.

#### SACT v3 update

The deadline to switch to SACT v3 submissions was February this year. SACT data are extremely important for the review of treatments and outcomes for patients being treated for cancer, and more recently for planning services during the COVID-19 pandemic.

information can be used to support mortality & morbidity meetings or other internal reviews.

#### Specialised Services Quality Dashboard (SSQD)

We will be providing quarterly metrics for the chemotherapy specialised services quality dashboard, with the first release due on 8th January 2021. This output is a deliverable of a major partnership between PHE and NHS England and NHS Improvement on SACT data. Once released, the dashboard will be available via the <a href="Quality Surveillance">Quality Surveillance</a> Programme portal (special access is required).

As always we welcome your feedback. Please send comments and suggestions for future newsletters to the SACT helpdesk SACT@phe.gov.uk

We appreciate the continued updates we receive from trusts on progress with implementation of SACT v3 and understand that the ongoing pandemic may have affected their ability to switch so far. However, in order to be compliant with the ISB information standard, trusts are required to submit SACT v3. For that reason, from April 2021 we will no longer be able to report on v2 data. Trusts will also be reported as non-compliant to NHS England and will be excluded from routine reports and other analyses. We aim to support trusts as much as possible; please contact the SACT helpdesk if you would like to discuss your situation further.

## The Cancer Drugs Fund (CDF)



During the last quarter of 2020, the team has focused on collecting and analysing data for the last final report due to in the new year. A busy year lies ahead, with 25 reports to produce, including 11 final reports. As NICE committee reviews continue, we also expect to publish more reports for final papers in the first half of next year. We continue to update the list of treatments funded by the CDF on our <a href="website">website</a> and the <a href="SACT Dataset Community">SACT Dataset Community</a>. We hope this will provide trusts with advanced notice of upcoming CDF collections to ensure CDF treatments are included in monthly SACT returns.

Thank you for continuing to support the team by responding to CDF queries over email and ensuring that any missing data is sent to us to contribute to our analyses.

#### Data liaison update

The data liaison officers continue to support trusts via email and telephone while trust visits are on hold. If you would like to request a call to discuss an issue, a challenge, or to receive some training on the dataset or <a href="CancerStats2">CancerStats2</a>, please contact the SACT <a href="helpdesk">helpdesk</a> who will put you in touch with the relevant member of the team. Following the release of the recent RDR and CMAR workbook, the team will be getting in touch with the trusts that were excluded from analyses to review current data completeness and discuss a data improvement plan.

#### Webinars

The team have hosted two webinars this quarter:

The CDF story: from NICE appraisal to routine commissioning - over 60 people registered to join this webinar which we hosted in collaboration with Professor Peter Clark, CDF Clinical Lead at NHS England. The webinar demonstrated how SACT data collected by NHS trusts are used by the National Institute for Health and Care Excellence (NICE) to determine whether drugs funded in the CDF should be made available through routine funding.

**SACT update for cancer commissioning pharmacists** - following discussions with several cancer commissioning pharmacists, this webinar was set up to provide an update on SACT v3, the CDF, recent 30-day mortality post-SACT analysis, and CancerStats2 reports, to ensure commissioning pharmacists have the information required to support their trust and region.

The recording and slide deck for both webinars are available to NHS staff registered on <a href="mailto:the SACT Dataset">the SACT Dataset</a> <a href="Community">Community</a>.

#### The SACT Dataset Community

The community provides an excellent opportunity for the SACT team to share updates on developments, host webinar recordings, share documents, release blog posts and provide event information. The online forum allows trusts to contact each other and share best practice.

Head to the community to access our recent blog post for breast cancer awareness month, detailing how SACT data are used to provide early access to promising new breast cancer treatments.

This platform is available for all NHS trust staff in

#### SACT regimen outcomes

#### Guidance to assess treatment benefit

On 19 November, we shared further guidance to support clinicians with reporting regimen outcomes for non-curative treatments. A detailed guidance document and a one-pager poster overview are now available to view on our website and the SACT Dataset Community. Please contact Claire Joussot with any feedback or further questions.

#### The outcomes upload

Thank you to all the trusts who have started to submit the additional outcomes upload; we are already England and can be accessed here <a href="www.khub.net/sact-dataset">www.khub.net/sact-dataset</a>. If you require any help with accessing or using the community, please contact <a href="mailto:nicolaE.wood@phe.gov.uk">nicolaE.wood@phe.gov.uk</a>.





#### Important links

SACT website - www.chemodataset.nhs.uk

Portal registration -

nww.cancerstats.nhs.uk/users/sign\_up

Portal access - nww.api.encore.nhs.uk/users/sign in

CancerStats2 registration -

www.cancerstats.ndrs.nhs.uk/user/register

CancerStats2 report access -

www.cancerstats.ndrs.nhs.uk/

observing a positive impact on outcomes data as shown in the reports on <a href="CancerStats2">CancerStats2</a>.

We are aware that some trusts are experiencing challenges switching to SACT v3 and will be unable to submit their first outcomes upload by the December 2020 deadline. We will not be reporting these trusts as non-compliant at this time, but will continue to work with them and will advise an amended submission deadline early 2021.

We would like to reiterate that once a trust has switched to SACT v3 data submissions, they can start/continue to submit the outcomes upload and are encouraged to do so.

More information on the outcomes upload is available on our website.

#### **Merry Christmas!**

The SACT team would like to wish you all a happy New Year and best wishes for the festive season. Thank you for your support throughout 2020; we look forward to continuing to work with you for a productive 2021!

You have been sent this newsletter because you have previously expressed an interest in the SACT dataset. If you are happy to continue to receive this newsletter you do not need to do anything. If you do not wish to receive future SACT newsletters please email <a href="mailto:SACT@phe.gov.uk">SACT@phe.gov.uk</a> and let us know if you want to be removed from the newsletter circulation list and/or other SACT communications. Alternatively you can click the unsubscribe button below.